CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $19.47M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 11.33: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
17.35BTWD545.36M · vs all stocks (USD)
Revenue (TTM)
619.48MTWD19.47M · vs all stocks (USD)
Profit Margin
-22.42%vs Biotechnology peers
Beta
-0.1440xvs all stocks
52-Week Change
-15.44%vs all stocks
Market Capitalization
17.35BTWD545.36M · vs all stocks (USD)
Enterprise Value
16.06BTWD504.69M · vs all stocks (USD)
Forward P/E
-58.79xvs Biotechnology peers
Price to Sales (TTM)
27.49xvs Biotechnology peers
Price to Book (MRQ)
4.67xvs Biotechnology peers
Enterprise to Revenue
25.92xvs Biotechnology peers
Gross Margin
50.70%vs Biotechnology peers
Profit Margin
-22.42%vs Biotechnology peers
Operating Margin
-47.91%vs Biotechnology peers
Return on Assets (TTM)
-2.52%vs Biotechnology peers
Return on Equity (TTM)
-3.66%vs Biotechnology peers
Revenue (TTM)
619.48MTWD19.47M · vs all stocks (USD)
Revenue per Share (TTM)
2.27TWDUpdated Sep 21, 2026Quarterly Revenue Growth
13.30%vs Biotechnology peers
Gross Profit (TTM)
283.54MTWD8.91M · vs all stocks (USD)
EBITDA (TTM)
-39.09MTWD-1.23M · vs all stocks (USD)
Net Income (TTM)
-138.90MTWD-4.37M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.30%vs Biotechnology peers
Operating Cash Flow (TTM)
155.12MTWD4.88M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
210.15MTWD6.60M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00TWDUpdated Sep 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
611.35MTWDFY2025 · Dec 31, 2025Cost of Goods Sold
351.90MTWDFY2025 · Dec 31, 2025Gross Profit
259.45MTWDFY2025 · Dec 31, 2025Operating Income
-194.65MTWD-6.12M · vs all stocks (USD)
Pre-tax Income
-167.78MTWDFY2025 · Dec 31, 2025Income Tax Expense
0.00TWDFY2025 · Dec 31, 2025Net Income
-167.78MTWDFY2025 · Dec 31, 2025EBIT
-157.06MTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-3.45MTWDFY2025 · Dec 31, 2025Research & Development
381.84MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
72.26MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
28.94MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
10.71MTWDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-167.78MTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
-148.85MTWDFY2025 · Dec 31, 2025Free Cash Flow
-171.51MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
898.38MTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-167.78MTWDFY2025 · Dec 31, 2025Stock-based Compensation
8.77MTWDFY2025 · Dec 31, 2025Other Non-cash Items
-18.23MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
11.08MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
17.31MTWDFY2025 · Dec 31, 2025Capital Expenditures
-22.67MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-99.00KTWDFY2025 · Dec 31, 2025Purchase of Investments
-83.85MTWDFY2025 · Dec 31, 2025Sale of Investments
260.55MTWDFY2025 · Dec 31, 2025Other Investing Activity
92.00KTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
154.12MTWDFY2025 · Dec 31, 2025Long-term Debt Payments
-27.24MTWDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00TWDFY2025 · Dec 31, 2025Other Financing Charges
-920.00KTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
-19.38MTWDFY2025 · Dec 31, 2025Shares Outstanding
270.70MSharesUpdated Sep 21, 2026Float Shares
182.12MSharesUpdated Sep 21, 2026% Held by Insiders
18.76%vs all stocks
% Held by Institutions
18.50%vs all stocks
Total Cash (MRQ)
1.60BTWD50.43M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.87TWDUpdated Sep 21, 2026Total Debt (MRQ)
478.14MTWD15.03M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1300xvs Biotechnology peers
Current Ratio (MRQ)
15.48xvs Biotechnology peers
Book Value per Share (MRQ)
13.46TWDUpdated Sep 21, 2026Total Assets
4.81BTWD151.20M · vs all stocks (USD)
Total Current Assets
3.32BTWDFY2025 · Dec 31, 2025Total Liabilities
953.05MTWDFY2025 · Dec 31, 2025Total Non-current Assets
1.49BTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
699.54MTWDFY2025 · Dec 31, 2025Total Current Liabilities
253.51MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
898.38MTWDFY2025 · Dec 31, 2025Other Short-term Investments
872.35MTWDFY2025 · Dec 31, 2025Accounts Receivable
64.65MTWDFY2025 · Dec 31, 2025Inventory
827.73MTWDFY2025 · Dec 31, 2025Accounts Payable
81.00MTWDFY2025 · Dec 31, 2025Short-term Debt
30.12MTWDFY2025 · Dec 31, 2025Other Current Liabilities
4.16MTWDFY2025 · Dec 31, 2025Long-term Debt
463.00MTWDFY2025 · Dec 31, 2025Common Stock (Book)
2.73BTWDFY2025 · Dec 31, 2025Retained Earnings
-1.30BTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
3.86BTWD121.24M · vs all stocks (USD)
52-Week Low
47.00TWDUpdated Sep 21, 202652-Week High
78.00TWDUpdated Sep 21, 202652-Week Change
-15.44%vs all stocks
Beta
-0.1440xvs all stocks
50-Day MA
61.62TWDUpdated Sep 21, 2026200-Day MA
57.58TWDUpdated Sep 21, 2026Avg 10-Day Volume
787.34KSharesUpdated Sep 21, 2026Avg 30-Day Volume
1.16MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-0.5000TWDUpdated Sep 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.51Profit Margin: -0.22
Financial Health
Altman Z-Score 11.33: safe zoneNotable
Altman Z-Score: 11.33
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $19.47M, lower than 95% of all stocks globallySignificant
Revenue (USD): 19,469,793.814Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhuhai Rundu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lifecome Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Delcath Systems Inc.
Tier 1ProductionApproval-Gated PipelineRule
Orchid Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Shen Lian Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai General Healthy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
BrainsWay Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Anhui Tatfook Technology Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Finolex Industries Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Suzhou Electrical Apparatus Science Academy Co. Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity